Zobrazeno 1 - 10
of 93
pro vyhledávání: ''
Autor:
Chris Twelves, Matthew Guo, Larisa Reyderman, Ishtiaq Husain Zubairi, R. Morrison, Nicola Cresti, Claudio Savulsky, Alan Anthoney, Vladimir Semiglazov, Ruth Plummer, T.R. Jeffry Evans, Constanta Timcheva
Publikováno v:
British Journal of Cancer
Background: \ud Capecitabine and eribulin are widely used as single agents in metastatic breast cancer (MBC) and have nonoverlapping toxicities.\ud \ud Methods: \ud In phase 1b (dose escalation), patients with advanced, treatment-refractory, solid tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97bccd2276eddef510b3a7b2fcc67aa0
https://eprints.whiterose.ac.uk/148290/1/s41416-018-0366-5.pdf
https://eprints.whiterose.ac.uk/148290/1/s41416-018-0366-5.pdf
Autor:
Laura A. Carleton, Laura Breen, Aidan P. Toner, Sharon A. Glynn, Francis J. Giles, Joe Lewis, F McLaughlin, Francis J. Sullivan, Adrienne M. Gorman, G Dunne, Enda O'Connell
Publikováno v:
British Journal of Cancer
Background: Taxanes are routinely used for the treatment of prostate cancer, however the majority of patients eventually develop resistance. We investigated the potential efficacy of EL102, a novel toluidine sulphonamide, in pre-clinical models of pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b0d73b25d4798f080df4b61b3dce051
http://hdl.handle.net/10379/14177
http://hdl.handle.net/10379/14177
Autor:
Takayoshi Ueno, Toru Kuratani, Koichi Toda, Toshiki Takahashi, Hiroyuki Nishi, Yoshiki Sawa, Takashi Kido, Masayuki Sakaki
Publikováno v:
General Thoracic and Cardiovascular Surgery
Objective To identify the predictive factors for responders to tolvaptan, a novel vasopressin type 2 receptor antagonist for fluid management after cardiovascular surgery. Methods Between January 2013 and May 2014, 113 patients were treated with tolv
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Background and Objectives Previous pharmacokinetic studies of the inhaled corticosteroid, fluticasone furoate (FF), and the long-acting, beta2-receptor agonist, vilanterol (VI) have been performed in relatively small populations using non-compartment
Autor:
Ian C. Reid, Justin H. G. Williams, Chamandeep K. Thind, Anthony Ormerod, Shantini A. Rice, Peter McCaffery
Publikováno v:
Psychopharmacology
Rationale The acne drug isotretinoin has 13-cis retinoic acid as its active agent. Adverse effects that have been described include severe depression. Animal studies indicate that the hippocampus is particularly sensitive to retinoic acid. Changes in
Autor:
Tamotsu Sagawa, Kan Yonemori, Kenji Tamura, Makoto Kodaira, Fumihiko Hirai, Toshio Kawata, Ben Hatano, Yuki Yokoi, Koshi Fujikawa, Yasuo Takahashi, Tsuyoshi Shirakawa, Taito Esaki
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose This was the first Phase I study to assess the safety and tolerability of the tablet formulation of olaparib (Lynparza™), an oral poly(ADP-ribose) polymerase inhibitor, in Japanese patients with advanced solid tumours. The pharmacokinetic p
Autor:
Dimitrios Avramopoulos, Constantine G. Lyketsos, Devangere P. Devanand, Jacobo Mintzer, Daniel Weintraub, Lon S. Schneider, David M. Shade, Robert R. Bies, Anton P. Porsteinsson, Bruce G. Pollock, Ayman Akil, Jerome A. Yesavage
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics
The citalopram for Alzheimer’s disease trial evaluated citalopram for the management for agitation in Alzheimer’s disease patients. Sparse data was available from this elderly patient population. A nonlinear mixed effects population pharmacokinet
Autor:
Hiroshi Nokihara, Tomohide Tamura, Hao Xiong, Vincent L. Giranda, Hideyuki Hashiba, Stacie Peacock Shepherd, Jane Qian, Shigehiro Yagishita, Shintaro Kanda, Satoru Kitazono, Yutaka Fujiwara, Hidehito Horinouchi, Hidenori Mizugaki, Noboru Yamamoto
Publikováno v:
Cancer Chemotherapy and Pharmacology
Abstact Introduction Veliparib is a potent, orally bioavailable PARP inhibitor that enhances efficacy of DNA-damaging chemotherapeutic agents. The study objectives were to determine the recommended phase 2 dose (RPTD) of veliparib plus carboplatin an
Publikováno v:
Archives of toxicology, 91(3), 1401-1412. SPRINGER HEIDELBERG
Archives of Toxicology
Archives of Toxicology
Hepatotoxicity is one of the major reasons for withdrawal of drugs from the market. Therefore, there is a need to screen new drugs for hepatotoxicity in humans at an earlier stage. The aim of this study was to validate human precision-cut liver slice
Publikováno v:
Journal of Gastroenterology
Background Vaniprevir (MK-7009) is a hepatitis C virus (HCV) non-structural 3/4a protease inhibitor which significantly increases virologic response rates in HCV genotype (GT) 1-infected patients when added to peginterferon and ribavirin (PR). Method